Literature DB >> 26422191

Synthetic cannabinoid hyperemesis resulting in rhabdomyolysis and acute renal failure.

Jacqueline R Argamany1, Kelly R Reveles1, Bryson Duhon2.   

Abstract

Synthetic cannabinoid usage has increased in the past decade. Concurrently, emergency management of associated adverse effects due to synthetic cannabinoid usage has also risen. Reported toxicities include psychosis, seizures, cardiotoxicity, acute kidney injury, and death. While cannabis was first described as a cause of acute hyperemesis in 2004, a more recent case series also describes the association between cannabinoid hyperemesis and risk of acute renal failure. Synthetic cannabinoids have also been reported to cause acute hyperemesis and acute renal failure; however, the risk of rhabdomyolysis-induced renal failure has yet to be elucidated. In this article, we report the first known case of synthetic cannabinoid hyperemesis leading to rhabdomyolysis and acute renal failure.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26422191     DOI: 10.1016/j.ajem.2015.08.051

Source DB:  PubMed          Journal:  Am J Emerg Med        ISSN: 0735-6757            Impact factor:   2.469


  9 in total

1.  Risk factors for kidney disease among HIV-1 positive persons in the methadone program.

Authors:  Bartłomiej Matłosz; Ewa Pietraszkiewicz; Ewa Firląg-Burkacka; Ewa Grycner; Andrzej Horban; Justyna D Kowalska
Journal:  Clin Exp Nephrol       Date:  2018-09-14       Impact factor: 2.801

2.  Running Out of Options: Rhabdomyolysis Associated with Cannabis Hyperemesis Syndrome.

Authors:  Bernard E Trappey; Andrew P J Olson
Journal:  J Gen Intern Med       Date:  2017-06-29       Impact factor: 5.128

Review 3.  Spice-y Kidney Failure: A Case Report and Systematic Review of Acute Kidney Injury Attributable to the Use of Synthetic Cannabis.

Authors:  Ceyda Zarifi; Shuchi Vyas
Journal:  Perm J       Date:  2017

Review 4.  Systematic review of nephrotoxicity of drugs of abuse, 2005-2016.

Authors:  Kanaan Mansoor; Murad Kheetan; Saba Shahnawaz; Anna P Shapiro; Eva Patton-Tackett; Larry Dial; Gary Rankin; Prasanna Santhanam; Antonios H Tzamaloukas; Tibor Nadasdy; Joseph I Shapiro; Zeid J Khitan
Journal:  BMC Nephrol       Date:  2017-12-29       Impact factor: 2.388

Review 5.  Opportunities for cannabis in supportive care in cancer.

Authors:  Amber S Kleckner; Ian R Kleckner; Charles S Kamen; Mohamedtaki A Tejani; Michelle C Janelsins; Gary R Morrow; Luke J Peppone
Journal:  Ther Adv Med Oncol       Date:  2019-08-01       Impact factor: 8.168

Review 6.  New psychoactive substances: a review and updates.

Authors:  Abu Shafi; Alex J Berry; Harry Sumnall; David M Wood; Derek K Tracy
Journal:  Ther Adv Psychopharmacol       Date:  2020-12-17

7.  Synthetic Cannabinoids and Cathinones Cardiotoxicity: Facts and Perspectives.

Authors:  Davide Radaelli; Alessandro Manfredi; Martina Zanon; Paolo Fattorini; Matteo Scopetti; Margherita Neri; Paolo Frisoni; Stefano D'Errico
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.708

Review 8.  Acute Kidney Injury (AKI) in Young Synthetic Cannabinoids Abusers.

Authors:  Stefano D'Errico; Martina Zanon; Davide Radaelli; Monica Concato; Martina Padovano; Matteo Scopetti; Paola Frati; Vittorio Fineschi
Journal:  Biomedicines       Date:  2022-08-10

Review 9.  Designer drugs: mechanism of action and adverse effects.

Authors:  Dino Luethi; Matthias E Liechti
Journal:  Arch Toxicol       Date:  2020-04-06       Impact factor: 5.153

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.